紫铆因

中文名称:

紫铆因

中文同义词:

紫铆因;紫铆查尔酮;紫铆花素;紫铆因标准品;蛋白质酪氨酸激酶抑制剂(BUTEIN);紫铆查耳酮;2-[2-(2-氨基苯基)乙烯基]-5-甲基-8-羟基喹啉;2-[2-(2-氨基苯基)乙烯基]-5-甲基-喹啉-8-醇

英文名称:

BUTEIN

英文同义词:

(E)-1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one 2,3,4,4-Tetrahydroxychalcone;BUTEIN(P);2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-, (2E)-;Butein 2,3,4,4-Tetrahydroxychalcone;2-[(E)-2-(2-aminophenyl)ethenyl]-5-methyl-quinolin-8-ol;2-[(E)-2-(2-aminophenyl)ethenyl]-5-methylquinolin-8-ol;2-[(E)-2-(2-aminophenyl)vinyl]-5-methyl-8-quinolinol;2-[(E)-2-(2-aminophenyl)vinyl]-5-methyl-quinolin-8-ol

CAS号:

487-52-5

分子式:

C15H12O5

分子量:

272.25

EINECS号:

207-659-5

相关类别:

对照品;细胞生物学试剂;小分子抑制剂，天然产物;合成;植物提取物;标准品;Aromatics;Inhibitors;Intermediates Fine Chemicals;Pharmaceuticals;标准品-对照品;新品;标准品 -对照药材;查尔酮;标准品，对照品

Mol文件:

487-52-5.mol

熔点 

216°C

沸点 

560.9±50.0 °C(Predicted)

密度 

1.483±0.06 g/cm3(Predicted)

储存条件 

-20°C

溶解度 

DMSO: >50 mg/mL

酸度系数(pKa)

7.44±0.35(Predicted)

形态

solid

颜色

yellow

CAS 数据库

487-52-5(CAS DataBase Reference)

生物活性

Butein，可从 Dalbergia odorifera T. Chen 分离，是一种 cAMP 特异性的 PDE 抑制剂，对 PDE4 的 IC50为 10.4 μM。Butein 是蛋白酪氨酸激酶抑制剂，对 EGFR 和 p60c-src 的 IC50 分别为 16 和 65 μM。Butein 通过 AKT 和 ERK/p38 MAPK 通路，靶向 FoxO3a 使 HeLa 细胞对 Cisplatin 敏感。Butein 还是一种 SIRT1 激活剂 (STAC)。

靶点

EGFR 16 μM (IC 50 , in HepG2 cells) PDE4 10.4 μM (IC 50 )

EGFR 16 μM (IC 50 , in HepG2 cells)

PDE4 10.4 μM (IC 50 )

体外研究

Butein potently inhibits cAMP-specific phosphodiesterase (type IV) activity with an IC 50 of 10.4±0.4 μM. In contrast, phosphodiesterase I, III and V activities were inhibited by Butein above 100 μM. Butein, a plant polyphenol, is a specific protein tyrosine kinase inhibitor. Butein inhibits not only the EGF-stimulated auto-phosphotyrosine level of EGFR in HepG2 cells but also tyrosine-specific protein kinase activities of EGFR (IC 50 =16 μM) and p60 c-src (IC 50 =65 μM) in vitro. Butein (10, 20, and 40 μM; 24, 48, and 72 hours) inhibits cell growth in a dose- and time-dependent manner. Butein exhibits anticancer activity through the inhibition of the activation of PKB/AKT and MAPK pathways, which are two pathways known to be involved in resistance to cisplatin. Butein (20 µM) decreases phosphorylation of AKT, ERK and p38 following 24 h of co-treatment with Cisplatin (20 µM). Cell Viability Assay Cell Line: HeLa cells Concentration: 10, 20, and 40 μM Incubation Time: 24, 48, and 72 hours Result: Inhibited cell growth in a dose- and time-dependent manner. Western Blot Analysis Cell Line: HeLa cells Concentration: 20 µM Incubation Time: 24 hours Result: Decreased phosphorylation of AKT, ERK and p38 co-treatment with Cisplatin (20 µM).

Cell Line:

HeLa cells

Concentration:

10, 20, and 40 μM

Incubation Time:

24, 48, and 72 hours

Result:

Inhibited cell growth in a dose- and time-dependent manner.

Cell Line:

HeLa cells

Concentration:

20 µM

Incubation Time:

24 hours

Result:

Decreased phosphorylation of AKT, ERK and p38 co-treatment with Cisplatin (20 µM).

体内研究

Butein (2 mg/kg every 2 days) in combination with Cisplatin (2 mg/kg every 2 days) for 3 weeks suppresses tumor growth in vivo. Animal Model: Nude mice (12 female 6- or 7-week old) with subcutaneous tumor xenografts Dosage: 2 mg/kg Administration: Intraperitoneally; every 2 days; for 3 weeks Result: Enhanced the antitumor effects of Cisplatin in vivo.

Animal Model:

Nude mice (12 female 6- or 7-week old) with subcutaneous tumor xenografts

Dosage:

2 mg/kg

Administration:

Intraperitoneally; every 2 days; for 3 weeks

Result:

Enhanced the antitumor effects of Cisplatin in vivo.

用途 

Butrin, isobutrin, and butein from medicinal plant Butea monosperma selectively inhibit nuclear factor-魏B in activated human mast cells: suppression of tumor necrosis factor-α, interleukin (IL)-6, and IL-8. Anti-inflammatory agent

安全说明 

22-24/25

WGK Germany 

3

海关编码 

29145090